- Home
- CTAA vs LUCD Comparison
CTAA vs LUCD Comparison
Compare CTAA & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$0.40
Company Overview
Basic Information| Metric | CTAA | LUCD |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 192.9M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CTAA | LUCD |
|---|---|---|
| Price | $10.03 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 92.7K | ★ 8.2M |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $33.93 |
| Revenue Next Year | N/A | $165.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $9.88 | $0.30 |
| 52 Week High | $10.10 | $1.63 |
Technical Indicators
Market Signals| Indicator | CTAA | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 37.39 |
| Support Level | $9.91 | $0.30 |
| Resistance Level | $10.10 | $1.09 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.16 | 36.58 |
Price Performance
Historical Comparison CTAA
LUCD
About CTAA ClearThink 1 Acquisition Corp. Class A Ordinary Shares
ClearThink 1 Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.